vs
MEDIFAST INC（MED）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是MEDIFAST INC的1.0倍（$75.5M vs $75.1M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -36.9%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $-6.6M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs -34.4%）
迈德福斯特是一家总部位于美国马里兰州巴尔的摩的营养减重企业，该公司研发、分销并销售减重及健康相关产品，销售渠道涵盖官方网站、多层次营销、电话销售以及品牌加盟减重诊所。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
MED vs PBYI — 直观对比
营收规模更大
PBYI
是对方的1.0倍
$75.1M
营收增速更快
PBYI
高出64.6%
-36.9%
自由现金流更多
PBYI
多$21.0M
$-6.6M
两年增速更快
PBYI
近两年复合增速
-34.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.1M | $75.5M |
| 净利润 | — | — |
| 毛利率 | 69.4% | 69.3% |
| 营业利润率 | -10.4% | 22.7% |
| 净利率 | — | — |
| 营收同比 | -36.9% | 27.7% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-1.64 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEDPBYI
| Q4 25 | $75.1M | $75.5M | ||
| Q3 25 | $89.4M | $54.5M | ||
| Q2 25 | $105.6M | $52.4M | ||
| Q1 25 | $115.7M | $46.0M | ||
| Q4 24 | $119.0M | $59.1M | ||
| Q3 24 | $140.2M | $80.5M | ||
| Q2 24 | $168.6M | $47.1M | ||
| Q1 24 | $174.7M | $43.8M |
净利润MEDPBYI
| Q4 25 | — | — | ||
| Q3 25 | $-2.3M | $8.8M | ||
| Q2 25 | $2.5M | $5.9M | ||
| Q1 25 | $-772.0K | $3.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.1M | $20.3M | ||
| Q2 24 | $-8.2M | $-4.5M | ||
| Q1 24 | $8.3M | $-4.8M |
毛利率MEDPBYI
| Q4 25 | 69.4% | 69.3% | ||
| Q3 25 | 69.5% | 77.7% | ||
| Q2 25 | 72.6% | 76.5% | ||
| Q1 25 | 72.8% | 77.1% | ||
| Q4 24 | 74.1% | 76.4% | ||
| Q3 24 | 75.4% | 63.9% | ||
| Q2 24 | 73.2% | 77.4% | ||
| Q1 24 | 72.8% | 75.5% |
营业利润率MEDPBYI
| Q4 25 | -10.4% | 22.7% | ||
| Q3 25 | -4.6% | 17.6% | ||
| Q2 25 | -1.0% | 12.7% | ||
| Q1 25 | -1.1% | 8.7% | ||
| Q4 24 | 0.6% | 22.6% | ||
| Q3 24 | 1.5% | 27.4% | ||
| Q2 24 | -4.7% | -4.6% | ||
| Q1 24 | 4.5% | -5.3% |
净利率MEDPBYI
| Q4 25 | — | — | ||
| Q3 25 | -2.5% | 16.2% | ||
| Q2 25 | 2.3% | 11.2% | ||
| Q1 25 | -0.7% | 6.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.8% | 25.2% | ||
| Q2 24 | -4.8% | -9.6% | ||
| Q1 24 | 4.8% | -11.0% |
每股收益（稀释后）MEDPBYI
| Q4 25 | $-1.64 | $0.26 | ||
| Q3 25 | $-0.21 | $0.17 | ||
| Q2 25 | $0.22 | $0.12 | ||
| Q1 25 | $-0.07 | $0.06 | ||
| Q4 24 | $0.08 | $0.40 | ||
| Q3 24 | $0.10 | $0.41 | ||
| Q2 24 | $-0.75 | $-0.09 | ||
| Q1 24 | $0.76 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.3M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $198.9M | $130.3M |
| 总资产 | $248.0M | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资MEDPBYI
| Q4 25 | $167.3M | $97.5M | ||
| Q3 25 | $173.5M | $94.4M | ||
| Q2 25 | $162.7M | $96.0M | ||
| Q1 25 | $164.6M | $93.2M | ||
| Q4 24 | $162.3M | $101.0M | ||
| Q3 24 | $170.0M | $96.7M | ||
| Q2 24 | $163.5M | $96.8M | ||
| Q1 24 | $156.4M | $107.2M |
总债务MEDPBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益MEDPBYI
| Q4 25 | $198.9M | $130.3M | ||
| Q3 25 | $214.7M | $115.3M | ||
| Q2 25 | $216.0M | $104.7M | ||
| Q1 25 | $211.0M | $97.1M | ||
| Q4 24 | $210.1M | $92.1M | ||
| Q3 24 | $207.3M | $71.1M | ||
| Q2 24 | $205.3M | $48.5M | ||
| Q1 24 | $211.0M | $51.0M |
总资产MEDPBYI
| Q4 25 | $248.0M | $216.3M | ||
| Q3 25 | $268.2M | $202.9M | ||
| Q2 25 | $269.3M | $194.9M | ||
| Q1 25 | $280.0M | $196.2M | ||
| Q4 24 | $284.2M | $213.3M | ||
| Q3 24 | $291.2M | $220.7M | ||
| Q2 24 | $293.5M | $205.0M | ||
| Q1 24 | $302.8M | $214.1M |
负债/权益比MEDPBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.3M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $-6.6M | $14.4M |
| 自由现金流率自由现金流/营收 | -8.8% | 19.1% |
| 资本支出强度资本支出/营收 | 1.8% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $1.2M | $41.7M |
8季度趋势，按日历期对齐
经营现金流MEDPBYI
| Q4 25 | $-5.3M | $14.4M | ||
| Q3 25 | $12.1M | $9.7M | ||
| Q2 25 | $-3.4M | $14.1M | ||
| Q1 25 | $3.4M | $3.6M | ||
| Q4 24 | $-4.9M | $15.6M | ||
| Q3 24 | $9.1M | $11.0M | ||
| Q2 24 | $13.1M | $1.0M | ||
| Q1 24 | $7.3M | $11.2M |
自由现金流MEDPBYI
| Q4 25 | $-6.6M | $14.4M | ||
| Q3 25 | $10.8M | $9.7M | ||
| Q2 25 | $-4.8M | $14.1M | ||
| Q1 25 | $1.9M | $3.6M | ||
| Q4 24 | $-7.2M | $15.6M | ||
| Q3 24 | $7.7M | $11.0M | ||
| Q2 24 | $11.1M | $1.0M | ||
| Q1 24 | $5.4M | — |
自由现金流率MEDPBYI
| Q4 25 | -8.8% | 19.1% | ||
| Q3 25 | 12.0% | 17.7% | ||
| Q2 25 | -4.5% | 26.8% | ||
| Q1 25 | 1.6% | 7.7% | ||
| Q4 24 | -6.1% | 26.4% | ||
| Q3 24 | 5.5% | 13.7% | ||
| Q2 24 | 6.6% | 2.1% | ||
| Q1 24 | 3.1% | — |
资本支出强度MEDPBYI
| Q4 25 | 1.8% | 0.0% | ||
| Q3 25 | 1.5% | 0.0% | ||
| Q2 25 | 1.3% | 0.0% | ||
| Q1 25 | 1.3% | 0.1% | ||
| Q4 24 | 1.9% | 0.0% | ||
| Q3 24 | 1.0% | 0.0% | ||
| Q2 24 | 1.1% | 0.0% | ||
| Q1 24 | 1.1% | 0.0% |
现金转化率MEDPBYI
| Q4 25 | — | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | -1.36× | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.04× | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
